Opportunity Information: Apply for RFA AG 17 011
Apply for RFA AG 17 011
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "From Association to Function in the Alzheimers Disease Post Genomics Era (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866,.
- This funding opportunity was created on May 11, 2016 and posted on May 11, 2016.
- Applicants must submit their applications by Sep 27, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "From Association to Function in the Alzheimers Disease Post Genomics Era (R21)" (Funding Opportunity Number RFA-AG-17-011) is a National Institutes of Health (NIH) discretionary grant program administered under HHS-NIH (listed as HHS-NIH11) within the health research activity category. It uses the NIH R21 mechanism, which is designed to support early stage, high-risk/high-reward, innovative, and exploratory projects that can open up new research directions rather than requiring a fully mature, long-term research plan. The scientific focus is Alzheimers disease, specifically the sporadic and late-onset forms, and the program is positioned in the "post-genomics" era where many genetic variants have already been statistically linked to disease risk but their biological roles remain unclear.
At its core, the FOA targets the gap between genetic association signals and actual disease mechanisms. Many Alzheimers-associated variants have been identified through approaches like genome-wide association studies, but association alone does not explain how a given variant changes cell biology or contributes to neurodegeneration. This announcement seeks projects that move from that association-level knowledge to functional understanding by examining how different Alzheimers disease genetic variants regulate proteins and protein complexes. The emphasis is on understanding protein structure and function, as well as how variants influence protein behavior in ways that matter biologically, such as altering enzymatic activity, stability, localization, post-translational modification, or participation in larger multiprotein assemblies.
A major priority in this FOA is platform development and application: investigators are encouraged to identify, build, or refine novel and effective methods to screen protein function, map protein-protein interactions, characterize protein complexes, and measure how these features are regulated by Alzheimers genetic variants. In practical terms, this could include developing scalable assays for detecting interaction changes caused by specific alleles, creating new experimental pipelines to compare variant-driven differences in complex assembly, or building screening systems that can evaluate many variants or protein targets efficiently. The announcement highlights protein-protein interactions and protein complexes because many disease-relevant effects of genetic variation are thought to operate through networks of interacting proteins rather than single proteins acting alone.
From an administrative and funding standpoint, the opportunity had an original and current closing date of September 27, 2016, and it was created and posted on May 11, 2016. The award ceiling is listed as $200,000, and the program expected to make about 4 awards. The CFDA numbers associated with the opportunity are 93.866, indicating it falls under an NIH funding line relevant to aging and Alzheimers-related research.
Eligibility is broad and includes a wide range of public and private entities. Eligible applicants include state, county, city or township governments, special district governments, and independent school districts, along with public and state-controlled institutions of higher education and private institutions of higher education. It also includes federally recognized Native American tribal governments, non-federally recognized tribal organizations, public housing authorities/Indian housing authorities, and nonprofit organizations both with and without 501(c)(3) status (as long as they are not institutions of higher education in those nonprofit categories). For-profit organizations other than small businesses, as well as small businesses, are also eligible, with a catch-all "others" category referring applicants to additional eligibility language in the full announcement.
Overall, the FOA is aimed at accelerating the field from genetic discovery to actionable biology by funding exploratory projects that can reveal what Alzheimers-associated variants actually do at the protein level. The program is especially aligned with projects that introduce new experimental capabilities or screening platforms that the community can use to systematically connect Alzheimers risk genetics to protein function, interactions, and complex regulation, thereby laying groundwork for clearer disease models and, potentially, new therapeutic strategies downstream.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "From Association to Function in the Alzheimers Disease Post Genomics Era (R21)."
What is the Funding Opportunity Number (FOA number)?
The FOA number is RFA-AG-17-011.
Which federal agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant program administered under HHS-NIH (listed as HHS-NIH11).
What type of grant mechanism does this opportunity use?
This opportunity uses the NIH R21 mechanism, which is intended to support early stage, high-risk/high-reward, innovative, and exploratory research projects. The emphasis is on opening up new research directions rather than requiring a fully mature, long-term research plan.
What research area does this opportunity focus on?
The scientific focus is Alzheimers disease, specifically sporadic and late-onset forms, in a "post-genomics" context where many genetic variants have already been statistically associated with disease risk but their biological roles remain unclear.
What core problem is this FOA trying to address?
The FOA targets the gap between genetic association signals (such as those discovered through genome-wide association studies) and functional disease mechanisms. It seeks projects that move beyond association to determine how Alzheimers-related genetic variants affect biology at the protein level.
What does "from association to function" mean in this program?
Within this program, "from association to function" refers to translating statistical links between genetic variants and Alzheimers risk into functional understanding, particularly by examining how different genetic variants regulate proteins and protein complexes in biologically meaningful ways.
What kinds of biological effects of variants are of interest?
The FOA emphasizes protein structure and function and is interested in how genetic variants influence protein behavior in ways that matter biologically, including changes to enzymatic activity, stability, localization, post-translational modification, and participation in larger multiprotein assemblies.
Why does the FOA emphasize protein-protein interactions and protein complexes?
The announcement highlights protein-protein interactions and protein complexes because many disease-relevant effects of genetic variation are thought to act through networks of interacting proteins rather than through single proteins acting alone.
What kinds of projects are especially encouraged?
A major priority is platform development and application. Investigators are encouraged to identify, build, or refine novel and effective methods to screen protein function, map protein-protein interactions, characterize protein complexes, and measure how these features are regulated by Alzheimers genetic variants.
What are examples of platform or method development activities mentioned in the description?
Examples described include developing scalable assays to detect interaction changes caused by specific alleles, creating experimental pipelines to compare variant-driven differences in complex assembly, and building screening systems that can evaluate many variants or protein targets efficiently.
Is this opportunity more focused on long-term, fully developed projects or exploratory work?
It is geared toward exploratory work. The R21 mechanism is designed for innovative, high-risk/high-reward projects that can open new research directions rather than requiring a fully mature, long-term research plan.
What is the funding ceiling for an award under this opportunity?
The award ceiling is listed as $200,000.
How many awards did the program expect to make?
The program expected to make about 4 awards.
What are the key dates provided for this opportunity?
The opportunity was created and posted on May 11, 2016. The original and current closing date is September 27, 2016.
What CFDA number is associated with this opportunity?
The CFDA number associated with the opportunity is 93.866.
What activity category is this opportunity listed under?
It is listed under the health research activity category.
Who is eligible to apply?
Eligibility is broad and includes a wide range of public and private entities, including governmental organizations, educational institutions, tribal entities, housing authorities, nonprofits, and for-profit organizations (including small businesses), plus an "others" category that refers applicants to additional eligibility language in the full announcement.
Are state and local governments eligible applicants?
Yes. Eligible applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Eligible applicants include federally recognized Native American tribal governments, as well as non-federally recognized tribal organizations.
Are public housing authorities eligible to apply?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
Are nonprofit organizations eligible?
Yes. Eligible applicants include nonprofit organizations with 501(c)(3) status (other than institutions of higher education) and nonprofit organizations without 501(c)(3) status (also other than institutions of higher education).
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
What is meant by the "post-genomics era" in the description?
In this context, "post-genomics" refers to the stage of research where many genetic variants have already been identified and statistically linked to Alzheimers disease risk, but there is still a major need to determine what those variants do biologically and how they contribute to disease mechanisms.
What is the program ultimately trying to accelerate?
The FOA aims to accelerate the field from genetic discovery to actionable biology by supporting exploratory projects that reveal what Alzheimers-associated variants do at the protein level, especially through protein function, interactions, and complex regulation. This work is positioned to lay groundwork for clearer disease models and potentially downstream therapeutic strategies.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Health
Next opportunity: Centers of Research Translation (CORT) (P50)
Previous opportunity: Ryan White HIV/AIDS Program Building Care and Prevention Capacity: Addressing the HIV Care Continuum in Southern Metropolitan Areas
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 17 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 17 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Centers of Research Translation (CORT) (P50) Apply for RFA AR 17 001 Funding Number: RFA AR 17 001 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Tuberculosis Vaccine Design (R01) Apply for PAR 16 254 Funding Number: PAR 16 254 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Mississippi Delta Health Collaborative Apply for CDC RFA DP16 1612 Funding Number: CDC RFA DP16 1612 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $3,150,000 |
| Public Health Preparedness and Response (PHPR) Cooperative Agreement for All-Hazards Public Health Emergencies: Zika 2016 Apply for CDC RFA TP16 1602 Funding Number: CDC RFA TP16 1602 Agency: HHS-CDC-OPHPR Category: Health Funding Amount: $5,000,000 |
| Grants for Early Medical/Surgical Subspecialists' Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 17 012 Funding Number: RFA AG 17 012 Agency: HHS-NIH11 Category: Health Funding Amount: $75,000 |
| From Association to Function in the Alzheimers Disease Post Genomics Era (R01) Apply for RFA AG 17 010 Funding Number: RFA AG 17 010 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Establishment of Centers of Excellence in Refugee Health Apply for CDC RFA CK15 150302CONT16 Funding Number: CDC RFA CK15 150302CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Learning Collaboratives for Advanced Business Acumen Skills Apply for HHS 2016 ACL CIP PPBA 0181 Funding Number: HHS 2016 ACL CIP PPBA 0181 Agency: HHS-ACL Category: Health Funding Amount: $500,000 |
| Creutzfeldt - Jakob Disease (CJD) Support, Education, and Awareness Projects as Apply for CDC RFA CK15 150402CONT16 Funding Number: CDC RFA CK15 150402CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Environmental Sampling with NAU for High Consequence Pathogens Apply for CDC RFA CK16 1606 Funding Number: CDC RFA CK16 1606 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: $300,000 |
| Children’s Hospitals Graduate Medical Education (CHGME) Payment Program Apply for HRSA 17 006 Funding Number: HRSA 17 006 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Jurisdictional Approach to Curing Hepatitis C Among HIV/HCV Coinfected People of Color - Evaluation and Technical Assistance Center Apply for HRSA 16 188 Funding Number: HRSA 16 188 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Inclusion of Mobile/e-Consents for Alzheimer's Disease Research (Admin Supp) Apply for PA 16 259 Funding Number: PA 16 259 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
| Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color – Jurisdictional Sites Apply for HRSA 16 189 Funding Number: HRSA 16 189 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R01) Apply for PAR 16 265 Funding Number: PAR 16 265 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R34) Apply for PAR 16 264 Funding Number: PAR 16 264 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) Apply for PAR 16 262 Funding Number: PAR 16 262 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities Outside the United States Apply for CDC RFA IP16 1603 Funding Number: CDC RFA IP16 1603 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $400,000 |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 16 267 Funding Number: PAR 16 267 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization Apply for CDC RFA IP16 1606 Funding Number: CDC RFA IP16 1606 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 17 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.